Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
The Pharma Data
OCTOBER 26, 2021
Q3 coreĀ¹ operating income grew +9% (cc, +10% USD) Innovative Medicines grew +13% (cc, +14% USD), due to higher sales and productivity programs Sandoz declined -15% (cc, -13% USD), impacted by gross margin Q3 operating income grew +32% (cc, +34% USD) Q3 net income increased +41% (cc, +43% USD) Q3 free cash flow 1 of USD 4.4 About Novartis.
Let's personalize your content